Navigation Links
Longhorn Vaccines & Diagnostics LLC Receives FDA Emergency Use Authorization (EUA) for the First 2009 H1N1 Influenza Assay to Include a Molecular Transport Medium (MTM)

SAN ANTONIO, Feb. 22 /PRNewswire/ -- Longhorn Vaccines & Diagnostics today announced it has been granted Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Longhorn Influenza A/H1N1-09 Prime RRT-PCR Assay™ in CLIA high complexity laboratories. . The Longhorn Influenza A/H1N1-09 Prime RRT-PCR Assay™ is a ready-use assay that requires no mixing prior to use and has been authorized for use on the ABI 7500.  The device includes PrimeStore MTM, a clinical collection and transport solution that preserves the released nucleic acids, including labile RNA for testing and contains an internal positive control, providing the first specimen collection solution to contain an internal RNA control capable of tracking the degradation of the sample from the point of collection.

"Sample integrity, and the ease and economy of transporting collected samples are key components to testing during outbreaks," said Gerald Fischer, MD, Longhorn Vaccines & Diagnostics' Chief Executive Officer. "An infectious disease physician and a molecular biologist designed The Longhorn Influenza A/H1N1-09 Prime RRT-PCR Assay™ to generate rapid, high quality PCR results, in as little as two hours while improving safety, and reducing laboratory preparation time."

2009 H1N1 is a new influenza virus that was detected in the United States in April 2009. As such, children and younger adults are less likely than older people to have immunity to this virus, and illness may be more severe and widespread as a result (1). In June 2009, the World Health Organization (WHO) announced that the spread of the novel 2009 H1N1 virus had reached pandemic phase 6, the highest level of pandemic alert designated by the organization (2).

"Influenza-like-illness puts a significant strain on Emergency Departments during the standard Influenza season.  The atypical epidemiology of H1N1-09 has magnified the impact on healthcare systems around the world.  The principal morbidity and mortality of H1N1-09 was in young, previously healthy patients who accessed the system in large numbers.  We were quite fortunate this time around that it came early, during relatively mild weather.  Having access to reliable, rapid testing will significantly improve the quality and timeliness of care we can provide -- in both hospital/ED, and community health settings," stated international health expert, R. Scott Altman MD, MPH, MBA, FACEP, Assistant Professor of Clinical Emergency Medicine at the Northwestern University Feinberg School of Medicine.

Longhorn Vaccines and Diagnostics will continue the development of the Longhorn Influenza A/H1N1-09 Prime RRT-PCR Assay™ and expects to submit a separate 510(k) in 2010.

About the FDA's Emergency Use Authorization

The US Secretary of Health and Human Services has declared a public health emergency because of the outbreak of the pandemic flu virus. The FDA has issued emergency use authorizations to make diagnostic and therapeutic tools available to public health and medical personnel for use in the diagnosis of 2009 H1N1 influenza virus under certain circumstances.

The FDA has not cleared or approved any tests for the identification of the 2009 H1N1 influenza virus. The emergency use authorization authority allows the FDA, based on the evaluation of available data, to authorize the use of unapproved and uncleared medical products following a determination and declaration of emergency, provided certain criteria are met. The FDA can only grant emergency use authorization for the duration of the emergency, which is currently set to expire on April 26, 2010, unless it is terminated sooner or renewed. The FDA may also revoke an EUA prior to the termination of the emergency.

About Longhorn Vaccines & Diagnostics

Longhorn Vaccines & Diagnostics is a private a biotech company located in San Antonio, TX that develops, and commercializes platform neutral RRT-PCR assays and develops vaccines for infectious diseases.

While initially focused on influenza diagnostics, Longhorn Vaccines & Diagnostics is working to develop PrimeMix assays for malaria, tuberculosis, dengue, and adenovirus. The company's proprietary molecular transport medium allows researchers to collect specimens from around the world and safely ship them to laboratories without expensive and cumbersome cold chain packaging including dry ice.  The PrimeStore MTM will facilitate standard sequencing and meta-genomic analysis of samples by improving the quality of the microbial nucleic acids in the collected specimens when they finally arrive in the laboratory.  

Longhorn Vaccines & Diagnostics is developing a proprietary universal influenza vaccine.  This vaccine is designed to provide broad protection against influenza viruses.  Its unique properties may make it easier, quicker, and less expensive to manufacture compared with standard influenza vaccines


(1) CDC: Facts About Novel H1N1 Influenza; May 2009


SOURCE Longhorn Vaccines & Diagnostics

Back to top



SOURCE Longhorn Vaccines & Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New method makes vaccines stable at tropical temperatures
2. Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents
3. BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines
4. Biological H1N1 Vaccines: Too Little, Too Late
5. Reportlinker Adds Cancer Vaccines: Measuring Market Potential
6. New Non-Biological Synthetic Replikins(TM) Vaccines Shown to Be Effective and Fast; WorldVaccines(TM), Ltd Formed for Testing and Distribution
7. ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria
8. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
9. IDRI Collaborates with the Brazilian Butantan Institute To Develop Novel Vaccines Against Leishmaniasis
10. China Bio-Immunity Corporation Initiates Voluntary Recalls of Rabies Vaccines
11. Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009
Post Your Comments:
(Date:11/26/2015)... MUMBAI , November 26, 2015 ... --> Accutest Research ... accredited Contract Research Organization (CRO), has ... Chase Cancer Center - Temple Health ... ,     (Photo: ) ...
(Date:11/25/2015)... 25, 2015 Studies reveal the ... plaque and pave the way for more effective treatment for ...     --> --> ... health problems in cats, yet relatively little was understood about ... studies have been conducted by researchers from the WALTHAM Centre ...
(Date:11/25/2015)... Nov. 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... in a fireside chat discussion at the Piper Jaffray ... . The discussion is scheduled for Wednesday, December ... .  A replay will be available for 14 ... , Julie NormartVP, Corporate Communications and Business Development ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... speaking at the following conference, and invited investors to ... NY      Tuesday, December 1, 2015 at 11.00 ... NY      Tuesday, December 1, 2015 at 11.00 ... Conference, New York, NY      Tuesday, ...
Breaking Biology Technology:
(Date:11/4/2015)... 4, 2015 --> ... published by Transparency Market Research "Home Security Solutions Market - ... 2015 - 2022", the global home security solutions market is expected ... 2022. The market is estimated to expand at a ... to 2022. Rising security needs among customers at homes, ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
(Date:10/27/2015)... Germany , October 27, 2015 ... SMI,s Automated Semantic Gaze Mapping technology (ASGM) automatically maps ... SMI,s Eye Tracking Glasses , so that they ... BeGaze. --> Munich, Germany , ... (ASGM) automatically maps data from mobile eye tracking videos ...
Breaking Biology News(10 mins):